Safety and efficacy of a digital therapeutic for substance use disorder: Secondary analysis of data from a NIDA clinical trials network study

References

• National Academies of Sciences Engineering and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press 2019.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). https://www.samhsa.gov/data/. Accessed October 28, 2021.
   Google Scholar
• Miller SC, Fielin DA, Rosenthal RN, Saitz R. The ASAM Principles of Addiction Medicine. 6th ed. Philadelphia, PA: Wolters Kluwer; 2018.
   Google Scholar
• Moore BA, Fazzino T, Garnet B, Cutter CJ, Barry DT. Computer-based interventions for drug use disorders: a systematic review. J Subst Abuse Treat. 2011;40(3):215–223.
   PubMed Web of Science ®Google Scholar
• Kiluk BD, Sugarman DE, Nich C, et al. A methodological analysis of randomized clinical trials of computer-assisted therapies for psychiatric disorders: toward improved standards for an emerging field. Am J Psychiatry. 2011;168(8):790–799.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Carroll KM, Kiluk BD. Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue. J Subst Abuse Treat. 2014;46(1):1–4.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions. Washington, DC: The National Academies Press; 2006.
   Google Scholar
• Lappan SN, Brown AW, Hendricks PS. Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis. Addiction 2020;115(2):201–217.
   PubMed Web of Science ®Google Scholar
• Food & Drug Administration. FDA permits marketing of mobile medical application for substance use disorder. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-mobile-medical-application-substance-use-disorder. Accessed January 26, 2021.
   Google Scholar
• Center for Devices and Radiological Health. De Novo Summary for reSET (DEN160018). Washington, DC: US Food and Drug Administration; 2017.
   Google Scholar
• Campbell AN, Nunes EV, Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683–690.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Marsch LA, Buchhalter AR, Badger GJ. Computerized behavior therapy for opioid-dependent outpatients: a randomized controlled trial. Exp Clin Psychopharmacol. 2008;16(2):132–143.
   PubMed Web of Science ®Google Scholar
• Christensen DR, Landes RD, Jackson L, et al. Adding an internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964–972.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Guarino H, Acosta M, et al. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat. 2014;46(1):43–51.
   PubMed Web of Science ®Google Scholar
• Maricich YA, Bickel WK, Marsch LA, Gatchalian K, Botbyl J, Luderer HF. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr Med Res Opin 2021;37(2):167–173.
   PubMed Web of Science ®Google Scholar
• Tseregounis IE, Gasper JJ, Henry SG. Trends in buprenorphine to treat opioid use disorder in California, 2012 to 2018: Medicaid outpaces the rest of the state. J Addict Med. 2021;15(5):425–428.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Saloner B, Dusetzina SB. Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015. Psychiatr Serv. 2018;69(7):832–835.
   PubMed Web of Science ®Google Scholar
• Campbell AN, Nunes EV, Miele GM, et al. Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network. Contemp Clin Trials. 2012;33(2):386–395.
   PubMed Web of Science ®Google Scholar
• Weisner C, Ray GT, Mertens JR, Satre DD, Moore C. Short-term alcohol and drug treatment outcomes predict long-term outcome. Drug Alcohol Depend. 2003;71(3):281–294.
   PubMed Web of Science ®Google Scholar
• Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol. 1988;49(3):219–224.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807–816.
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511–2518.
   PubMed Web of Science ®Google Scholar
• National Institute on Drug abuse. Health consequences of drug misuse. National Institute on Drug abuse. https://www.drugabuse.gov/related-topics/health-consequences-drug-misuse. Published 2017. Accessed November 26, 2019.
   Google Scholar
• Cochran G, Stitzer M, Campbell AN, Hu MC, Vandrey R, Nunes EV. Web-based treatment for substance use disorders: differential effects by primary substance. Addict Behav. 2015;45:191–194.
   PubMed Web of Science ®Google Scholar
• Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004;55(7):767–774.
   PubMed Web of Science ®Google Scholar
• Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency. BMC Health Serv Res. 2011;11:174.
   PubMed Web of Science ®Google Scholar
• Maricich YA, Xiong X, Gerwien R, et al. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder. Curr Med Res Opin 2021;37(2):175–183.
   PubMed Web of Science ®Google Scholar
• Velez FF, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K. Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):69–76.
   PubMed Web of Science ®Google Scholar
• Rosenbaum J, Lucas N, Zandrow G, et al. Impact of a shelter-in-place order during the COVID-19 pandemic on the incidence of opioid overdoses. Am J Emerg Med. 2021;41:51–54.
   PubMed Web of Science ®Google Scholar
• Wainwright JJ, Mikre M, Whitley P, et al. Analysis of drug test results before and after the US declaration of a national emergency concerning the COVID-19 outbreak. JAMA 2020;324(16):1674.
   PubMed Web of Science ®Google Scholar